Key Highlights
- MANE shares fell 3.56% pre-market today to $150.99, after closing Wednesday at $156.56.
- Cash, cash equivalents and marketable securities totaled $798.4 million at September 30.
- Third quarter net loss was $21.0 million, versus $20.1 million a year earlier.
- Study '302' showed a mean gain of 43.9 hairs/cm2 at Month 12 on the twice-daily dose.
- General and administrative expenses rose to $12.7 million from $2.3 million.
Veradermics (NYSE:MANE) shares slipped pre-market today, a day after the stock closed up 5.47% at $156.56, near the top of its 52-week range of $32.00 to $156.63. The stock was quoted at $150.99, down 3.56%. The company reported third quarter results on Tuesday alongside new clinical data.
Veradermics is a dermatologist-founded, late-stage biopharmaceutical company based in New Haven, Connecticut. Its lead candidate, VDPHL01, is an oral, non-hormonal extended-release minoxidil tablet in Phase 3 development for pattern hair loss in men and women.
12-Month Study '302' Data and the Phase 3 '304' Readout
In November, Veradermics reported 12-month results from Phase 2/3 Study '302' in men. Participants on the continued twice-daily 8.5 mg dose gained a mean 43.9 hairs/cm2 in non-vellus target area hair count, while the once-daily arm gained 29.7 hairs/cm2. The company said 89.1% of the twice-daily arm reported visible improvement in hair coverage.
In October, the company said Phase 3 Study '304' met all primary and secondary endpoints. At six months, mean hair count rose 36.4 hairs/cm2 on the twice-daily dose and 28.6 hairs/cm2 on the once-daily dose. Veradermics reported no treatment-related serious adverse events and no cardiac adverse events of special interest.
$798.4 Million in Cash Meets a Rising General and Administrative Bill
Cash, cash equivalents and marketable securities were $798.4 million at September 30, up from $141.9 million at December 31, 2025. The company expects that cash to fund operations into 2030 through multiple Phase 3 readouts and a potential launch. Total liabilities were $10.7 million.
Net loss was $21.0 million versus $20.1 million a year earlier, and the nine-month net loss was $71.7 million. Research and Development expenses fell to $16.1 million from $18.1 million, while general and administrative expenses rose to $12.7 million from $2.3 million. The company tied the increase mainly to Payroll costs, including $3.1 million more in stock-based compensation, plus commercial readiness costs and professional fees. Interest income was $5.1 million.
Female Pattern Hair Loss Study '306' Is the Next Catalyst
Enrollment is complete in Study '306', which the company describes as the first registration-directed trial of an oral therapy specifically for women with pattern hair loss in the United States. Topline data are expected in the first half of 2027. In July, an open-label Phase 2 study in women reported rapid onset and consistent hair growth, according to the company.
Pullback From the Yearly High Leaves 2027 Data as the Next Marker
The shares are trading below Wednesday's close, which sat near the top of the 52-week range. Study '306' topline data in the first half of 2027 and preparations for a potential commercial launch are the next items to watch.






Please wait processing your request...